MedTrace Logo

Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

NCT06272799 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2024-09-19

No results posted yet for this study

Summary

Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.

Conditions

Interventions

DRUG

T-DM1 adjuvant

Evaluate the tolerability of treatment with adjuvant T-DM1 after failure to respond complete pathology to neoadjuvant treatment in terms of adverse events

Sponsors & Collaborators

  • Regina Elena Cancer Institute

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-20
Primary Completion
2024-09-20
Completion
2024-09-20

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06272799 on ClinicalTrials.gov